Zentalis adopts amended bylaws with universal proxy rule compliance

Zentalis Pharmaceuticals, Inc.

Board approved Amended and Restated Bylaws effective February 12, 2024.
Amendments address SEC universal proxy rules under Rule 14a-19, including notice and solicitation requirements.
Enhanced disclosure requirements for stockholder director nominations and other business proposals.
Prohibits proposing more nominees than directors up for election.
Includes technical, modernizing, clarifying, and conforming changes.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Zentalis Pharmaceuticals, Inc.: Amended and Restated Bylaws to address universal proxy rules, streamline stockholder nomination procedures, and prohibit excessive director nominees; effective February 12, 2024 (effective 2024-02-12).

Change: bylaw amendment
Effective: 2024-02-12

Exact text from the filing

On February 12, 2024, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc., a Delaware corporation (the “Company”) approved and adopted amendments to the Company’s Bylaws (as amended, the “Amended and Restated Bylaws”), which became effective the same day.

View on SEC.gov

188 governance changes filed in the last 30 days. Browse all governance changes →

Zentalis Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001725160-24-000057

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.